Metabolism of Macromolecular Heparin in Mouse Neoplastic
Heparin is a glycosaminoglycan endowed with unique biological properties, the best-known of which are its anticoagulant and lipolysis-stimulating activities (Ehrlich & Stivala, 1973) . The polysaccharide is synthesized by mast cells (Selye, 1965) , and possibly by basophilic leucocytes (Olsson et al., 1970) , and is stored within the cells in granules containing, in addition, protein and vasoactive amines.
Most glycosaminoglycans occur in the native state as proteoglycans, composed of several polysaccharide chains covalently linked to a common polypeptide core (Lindahl & Roden, 1972) . Attempts to isolate a heparin proteoglycan were unsuccessful, yielding essentially single polysaccharide chains, with mol.wts. ranging from 7000 to about 25000 (Lindahl, 1970; Ogren & Lindahl, 1971; Jansson et al., 1975) . However, in rodent tissues heparin has been shown to -occur as a multichain macromolecular species (mol.wt. up to 1000000) quite different from 'conventional' proteoglycans (Horner, 1971; Ogren & Lindahl, 1971) ; in this rodent heparin molecule, the individual polysaccharide chains are joined in a so far unknown manner, Vol. 154 possibly by a polysaccharide core (Horner, 1971) . Horner (1972) (Ogren & Lindahl, 1971) . Since that time an enzyme has been isolated (from the same tissue) which degrades macromolecular heparin to single polysaccharide chains, similar in size to commercially available heparin (Ogren & Lindahl, 1975a) . The liberated polymer molecules were resistant to further degradation. The enzyme (hereafter termed 'heparin-liberating enzyme') was tentatively identified as an endoglucuronidase. Evidence has been obtained suggesting that the formation and degradation of macromolecular heparin may also occur in mammals other than rodents (see Jansson et al., 1975) .
The present investigation was undertaken to obtain further information about the intracellular metabolism of the newly synthesized heparin. The results show that degradation of the polysaccharide occurs in a particulate fraction that sedi. 20min at 20000g; the degradation pr largely transferred to particles that sedi 10min at 1000g. The heparin-liberating localized in particles in the 20000g which share some properties with lysosoi A preliminary report of some of this already appeared (Ogren & Lindahl, 197 Experimental Materials
The transplantable, mouse mastocytor this study has been described previously Lindahl, 1971 and 10mg of enzyme protein (Lindahl et al., 1973 ; the UDP-N-acetylglucosamine concentration was chosen to give maximal polymerase activity); the final incubation volumes were 75g1. After incubation at 37°C for 60min the mixtures were heated at 1000C for 3niin and digested overnight at 55°C with Pronase (10,u of a solution containing 10mg of enzyme/ml). The digests were centrifuged, and were then analysed for labelled polysaccharide by the method of Wasteson et al. (1973) . Samples (50,ul) of the supernatants were applied to strips of Whatman 3MM filter paper; the strips were dried and subsequently washed for 30min in each of five changes of 1 % (w/v) cetylpyridinium chloride in 0.05M-NaCl.
'IC-labelled polysaccharide was measured by liquidscintillation counting, as described by Wasteson et al. (1973) .
Heparin-liberating enzyme in subcellularfractions
The 10OOg and 20000g fractions were tested for heparin-liberatingenzyme as follows. Portions (1 ml) of each pellet, corresponding to approximately equal amounts of tumour tissue, were suspended in 2ml of 0.25M-sucrose/0.05M-Tris/HCI, pH7.4. Samples (0.9ml) of the suspensions and of a 20000g supernatant were mixed with 0.1 ml of 0.5M-sodium acetate buffer, pH5.0 (pH optimum determined for the isolated enzyme; Ogren & Lindahl, 1975a) ; samples (0.5ml) were frozen and thawed and were then incubated with macromolecular 35S-labelled heparin (3 x 104c.p.m.) at 37°C in a stirred water bath.
After 24h the incubation mixtures were heated at 100°C for 5min and were then diluted with an equal volume of 4M-NaCl, containing 0.02M-cysteine hydrochloride and 0.02M-EDTA. Papain (0.1 ml) was added and the samples were digested at 65°C for 30min, boiled, clarified by centrifugation and analysed by gel chromatography.
Density-gradient centrifugation of 20000g fraction
Each of three tumour-bearing mice was injected with (35SJsulphate, as described above; 4h.later the Vol. 154 mice were killed and the tumours were removed and homogenized. The 20000g fraction was prepared and subjected to density-gradient centrifugation in the iso-osmotic colloidal silica (Ludox HS)/polyvinylpyrrolidone medium (PEL-1.055) described by Wolff & Pertoft (1972) . The 20000g fraction, suspended in 5 ml of0.25 M-sucrose, was layered in 1 ml portions on top of the gradient solution in five centrifuge tubes (each containing 11.5ml of gradient medium) and was then centrifuged at 30000rev./min (80000g) in a Beckman L4 ultracentrifuge (rotor* 30.2) for 20min. Fractions (about 1.5ml) were collected and their density was measured (Miller & Gasek, 1960) . They were then mixed with Triton X-100 (final concentration 0.1 %, v/v) and finally analysed for radioactivity and for f-glucuronidase activity after freezing and thawing of the samples. Before analysis for heparin-liberating enzyme, fractions were pooled as indicated in Fig. 4 The distribution with time of 35S-labelled polysaccharide between the various subcellular fractions is illustrated in Fig. 1 (Fig. 1) . The amounts of labelled polysaccharide in the 100OOOg pellet and supernatant fractions remained low throughout the experiment.
The results of the radiochemical experiments can be related to the subeellular distribution of the unlabelled bulk polysaccharide (Table 1) . The polysaccharide recovered from the various subcellular fractions together accounted for 85 % of the total sulphated glycosaminoglycuronan of the mastocytoma tissue. The major portion (90 %) of the total polysaccharide occurred in particles sedimenting at 20000g, and was about evenly distributed between the 10OOg and the 20000g fractions. These relations are in fair agreement with the subcellular distribution of 35S-labelled polysaccharide when recorded 24h after injection of [35S]sulphate (Fig. 1) . Fig. 1 shows that the amounts of 35S-labelled polysaccharide in the 20000g and the 100000g fractions decreased in parallel during the first hour after [35S]sulphate injection; thus no redistribution of labelled material from the latter to the former fraction was observed. As 35S was initially incorporated mostly into the 20000g fraction, probably most of the polysaccharide produced by the tumour cells was actually formed in this fraction rather than in the 10OOOOg ('microsomal') fraction. This conclusion was supported by experiments in which each of the two fractions was incubated with UDP-["C]glucuronic acid in the presence of unlabelled UDP-Nacetylglucosamine. The data given in Table 1 , expressed as amounts of 14C-labelled polysaccharide formed/mg of protein, must be considered in relation to the total protein contents of the fractions; the overall polymerase activity then appears to be higher in the 20000g than in the 100000g fraction. Although these results may not be directly applicable to the situation in vivo, they clearly demonstrate that the ability to synthesize glycosaminoglycans is not restricted to the microsomal fraction.
Molecular size ofglycosaminoglycans labelled in vivo with [35S]sulphate
The molecular size of 3RS-labelled glycosaminoglycans was investigated by gel chromatography on Sepharose 4B. The gel chromatograms illustrated in Fig. 2 refer to the preparations isolated from the 20000g fraction at various times after injection of the mice with (35S]sulphate. The material obtained after 30min showed a major peak of high-molecularweight labelled material, with smaller amounts of more retarded components. With increasing time a progressive shift towards lower molecular weight was observed; the elution pattern of 35S-labelled polysaccharide isolated 6h or more after injection was similar to that of the bulk polysaccharide of the tissue (see Ogren & Lindahl, 1971) . conformed to those illustrated in Fig. 2 ; however, the polysaccharide obtained 30min after injection of [35S]sulphate contained relatively more lowmolecular-weight components than thecorresponding material from the 20000g fraction. The 5S-labelled polysaccharide preparations obtained from the lOOOOOg supernatant were all retarded equally on gel chromatography, irrespective of time of isolation. Subcellular location of mastocytomal heparin-liberating enzyme Subcellular fractions were tested for heparinliberating enzyme by incubation with macromolecular [35S]heparin, followed by gel chromatography on Sepharose 4B (see the Experimental section). Incubation of the substrate with the 10OOg fraction (Fig. 3) or with the 20000g supernatant (not shown) did not result in any significant degradation. By contrast, appreciable breakdown of the 35S-labelled polys4ccharide was noted after incubation with the 20D0g fraction. Although these results cannot be quantitatively evaluated in terms of enzyme activity, they suggest that the heparin-liberating enzyme occurs preferentially in the 20000g fraction. The low activity of the 10OOg fraction should probably not be ascribed to inhibitory effects of endogenous heparin (Ogren & Lindahl, 8 .7 Fraction no. (Fig. 4) .
This band contained all the fl-glucuronidase and 35S recovered in the 20000g fraction. Further, all the heparin-liberating enzyme of the 20000g fraction was associated with the banded particles (i.e. the middle group of Fig. 4 (Fig. 1) would not obey strict pulse-chase kinetics. Interpretation oftheseresults is furthercomplicated bythe metabolic heterogeneity of the cell population in the tumour tissue. Previous studies by Pertoft (1970) , with the same mastocytoma as was used in the present investigation, showed the presence of at least four fractions of mast cells, some of which differed markedly with regard to heparin-synthesizing capacity. The relative amounts of the various cell types in tumours at different stages of development is unknown; it is noteworthy that the tumour approximately doubles its size in 24h. From these considerations it is evident that the results obtained, bearing on the degradation and subcellular distribution of heparin, should be evaluated with some caution. However, the following conclusions seem to be justified.
Heparin is synthesized in subcellular particles, a major fraction of which may be recovered by centrifugation at 20000g. The assembly of an individual polysaccharide molecule probably occurs within a few minutes or less; studies on the cell-free biosynthesis of glycosaminoglycans suggest that both polymer formation and sulphation Hook et al., 1975) are rapid processes. The product is a complex macromolecule, with a molecular weight considerably exceeding that of commercially available heparin (Ogren & Lindahl, 1971) . Within the first hour after biosynthesis the macromolecular heparin is transferred to particles sedimenting, at lOOOg; alternatively, the particles containing the newly synthesized polysaccharide become-modified, and acquire altered sedimentation properties. In association with this -shift, the macromolecular heparin is degraded, ultimately to the size of commercial heparin (Open & Lindahl, 1975a) . The degradation process appears to be essentially complete within 6h after biosynthesis (this period oftime, as indicated by gel-chromatography patterns of the kind shown in Fig. 2 , may, however, have been overestimated owing to the contribution of high-molecular-weight 35S-labelled polysaccharide formed after the pulse period).
The particles containing heparin-liberating enzyme were characterized further by density-gradient centrifugation in colloidal silica. The low density thus recorded is similar to that observed for lysosomes in the same medium (H. Pertoft, personal communication) . The similarities to lysosomes also include the presence of f8-glucuronidase. However, additional work is required to establish the true nature of these particles and their functional relationship to other cell organelles, particularly the mast-cell granules serving as place of storage for the final heparin product.
The occurrence of heparin-liberating enzyme is not restricted to neoplastic mast cells, as similar enzymes have been demonstrated in small intestine and spleen from both rat and man (Horner, 1972; S. Ogren, unpublished work) . Further, heparin isolated from bovine liver capsule showed the structural properties expected (i.e. a molecular weight similar to commercial heparin and lack of a carbohydrate-protein linkage region) for the singlechain product released from macromolecular heparin by heparin-liberating enzyme (Jansson et al., 1975) . Macromolecular hepar'i has been isolated not only from rodents but also from monkey and man (Horner, 1970) . It 
